<p>根據 Kennedy Capital Management LLC 最近向證券交易委員會提交的 13F 文件，該公司在第二季度將其在 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免費報告）股票中的持股增加了 380.2%。該公司在季度內額外購買了 22,133 股後，持有 27,955 股。根據其最近的 SEC 文件，Kennedy Capital Management LLC 持有 Axsome Therapeutics 的股份佔比為 0.06%，價值 2,918,000 美元。</p>
<p>獲取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
<ul>
<li>5 只醫療股票的收益增長超過三位數</li>
</ul>
<p>其他一些對沖基金也增加或減少了在 AXSM 的持股。Caitong International Asset Management Co. Ltd 在第一季度購買了價值約 25,000 美元的 Axsome Therapeutics 新股份。Quantbot Technologies LP 在第一季度收購了價值約 31,000 美元的 Axsome Therapeutics 新股份。AlphaQuest LLC 在第一季度收購了價值 38,000 美元的 Axsome Therapeutics 新股份。BI Asset Management Fondsmaeglerselskab A S 在第一季度購買了價值約 47,000 美元的 Axsome Therapeutics 新股份。最後，Ameritas Advisory Services LLC 在第二季度購買了價值約 77,000 美元的 Axsome Therapeutics 新股份。目前，81.49% 的股票由機構投資者持有。</p>
<h2>內部買賣</h2>
<p>在相關消息中，首席運營官 Mark L. Jacobson 於 9 月 22 日星期一出售了 10,000 股該股票。股票以 115.96 美元的平均價格出售，總價值為 1,159,600.00 美元。該交易在 SEC 的法律文件中披露，相關信息可通過此超鏈接獲取。此外，首席執行官 Herriot Tabuteau 於 12 月 4 日星期四出售了 10,558 股公司的股票。股票以 148.18 美元的平均價格出售，總價值為 1,564,484.44 美元。交易後，首席執行官直接持有 7,229 股公司的股票，價值 1,071,193.22 美元。該交易使其持股減少了 59.36%。該銷售的披露信息可在 SEC 文件中找到。在過去 90 天內，內部人士出售了價值 52,645,040 美元的 407,959 股公司股票。內部人士持有公司 22.30% 的股票。</p>
<h2>Axsome Therapeutics 價格表現</h2>
<ul>
<li>struggling Axsome 股票可能因藥物試驗成功而反彈</li>
</ul>
<p>AXSM 的股票在週五開盤價為 149.22 美元。該公司的 50 日移動平均價格為 134.97 美元，200 日移動平均價格為 118.87 美元。該股票的市值為 75.2 億美元，市盈率為-31.95，貝塔值為 0.48。該公司的債務與股本比率為 1.66，流動比率為 1.57，速動比率為 1.50。Axsome Therapeutics, Inc.的 1 年最低價為 75.56 美元，1 年最高價為 152.94 美元。</p>
<p>Axsome Therapeutics（NASDAQ:AXSM - 獲取免費報告）最近在 11 月 3 日星期一發布了季度收益數據。該公司報告季度每股收益（EPS）為（0.94 美元），低於市場共識預期的（0.82 美元）0.12 美元。Axsome Therapeutics 的股本回報率為-277.31%，淨利潤率為-40.90%。該業務在本季度的收入為 1.7099 億美元，而分析師預期為 1.6296 億美元。Axsome Therapeutics 的季度收入同比增長 63.2%。作為一個整體，賣方分析師預計 Axsome Therapeutics, Inc.在當前年度將發佈-2.79 的每股收益。</p>
<h2>分析師評級變動</h2>
<ul>
<li>為什麼現在是購買 Axsome Therapeutics 的絕佳時機</li>
</ul>
<p>幾位股票分析師最近對該公司進行了評估。Needham &amp; Company LLC 重申了對 Axsome Therapeutics 股票的 “買入” 評級，並在 11 月 4 日的研究報告中給出了 154.00 美元的目標價。加拿大皇家銀行將 Axsome Therapeutics 的目標價從 189.00 美元上調至 198.00 美元，並在 11 月 4 日的研究報告中給予該公司 “跑贏大盤” 的評級。瑞穗證券在 11 月 6 日的報告中將 Axsome Therapeutics 的目標價從 200.00 美元上調至 202.00 美元，並給予該股票 “跑贏大盤” 的評級。摩根士丹利在 11 月 4 日的報告中將 Axsome Therapeutics 的目標價從 194.00 美元上調至 196.00 美元，並給予該公司 “增持” 的評級。最後，B. Riley 在 10 月 1 日的研究報告中開始覆蓋 Axsome Therapeutics 的股票。他們設定了 “買入” 評級和 179.00 美元的目標價。一位股票研究分析師對該股票給予了強烈買入評級，十六位給予了買入評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價為 179.88 美元。</p>
<p><strong>查看我們關於 Axsome Therapeutics 的最新報告</strong></p>
<h2>關於 Axsome Therapeutics</h2>
<p>（免費報告）</p>
<p>Axsome Therapeutics, Inc.是一家生物製藥公司，專注於在美國開發針對中樞神經系統（CNS）疾病的新療法。該公司的商業產品組合包括 Auvelity（右美沙芬 - 布普洛尼），這是一種具有多重作用的 N-甲基-D-天冬氨酸受體拮抗劑，適用於治療重度抑鬱症；以及 Sunosi（索利美特），這是一種用於治療嗜睡症或阻塞性睡眠呼吸暫停患者的白天過度嗜睡的藥物。</p>
<h2>另請參閲</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Axsome Therapeutics</li>
<li>投資者如何識別併成功交易缺口下跌股票</li>
<li>Ulta 的股票可能會迎來反彈——20% 的上漲空間？</li>
<li>最佳航空航天股票投資</li>
<li>比爾和梅琳達·蓋茨基金會出售 MSFT 股票——投資者應該擔心嗎？</li>
<li>股息捕捉策略：您需要知道的事項</li>
<li>MarketBeat 週迴顧 – 12/1 - 12/5</li>
</ul>
<p><strong>想看看其他對沖基金持有 AXSM 的情況嗎？</strong> 訪問 HoldingsChannel.com 以獲取 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Axsome Therapeutics 嗎？</h2>
<p>在考慮 Axsome Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Axsome Therapeutics 並不在名單上。</p>
<p>雖然 Axsome Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AXSM

<p>肯尼迪資本管理公司在第二季度將其在 Axsome Therapeutics, Inc.的持股增加了 380.2%，目前持有 27,955 股，價值 2,918,000 美元。分析師們給予了積極的評級，目標價格範圍在 154 美元到 202 美元之間，顯示出潛在的增長。內部人士在過去 90 天內出售了價值 52,645,040 美元的股票。Axsome 的股票開盤價為 149.22 美元，市值為 75.2 億美元</p>

<p>Kennedy Capital Management LLC boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 380.2% in the second quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 27,955 shares of the company's stock after acquiring an additional 22,133 shares during the quarter. Kennedy Capital Management LLC owned 0.06% of Axsome Therapeutics worth $2,918,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根據 Kennedy Capital Management LLC 最近向證券交易委員會提交的 13F 文件，該公司在第二季度將其在 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免費報告）股票中的持股增加了 380.2%。該公司在季度內額外購買了 22,133 股後，持有 27,955 股。根據其最近的 SEC 文件，Kennedy Capital Management LLC 持有 Axsome Therapeutics 的股份佔比為 0.06%，價值 2,918,000 美元。</p>
</div><p>Get <strong>Axsome Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Axsome Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只醫療股票的收益增長超過三位數</li>
</ul>
</div><p>A number of other hedge funds have also added to or reduced their stakes in AXSM. Caitong International Asset Management Co. Ltd bought a new stake in Axsome Therapeutics during the first quarter valued at about $25,000. Quantbot Technologies LP acquired a new stake in shares of Axsome Therapeutics during the first quarter worth about $31,000. AlphaQuest LLC acquired a new stake in shares of Axsome Therapeutics in the first quarter worth $38,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Axsome Therapeutics during the 1st quarter valued at about $47,000. Finally, Ameritas Advisory Services LLC purchased a new position in Axsome Therapeutics during the second quarter valued at approximately $77,000. 81.49% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些對沖基金也增加或減少了在 AXSM 的持股。Caitong International Asset Management Co. Ltd 在第一季度購買了價值約 25,000 美元的 Axsome Therapeutics 新股份。Quantbot Technologies LP 在第一季度收購了價值約 31,000 美元的 Axsome Therapeutics 新股份。AlphaQuest LLC 在第一季度收購了價值 38,000 美元的 Axsome Therapeutics 新股份。BI Asset Management Fondsmaeglerselskab A S 在第一季度購買了價值約 47,000 美元的 Axsome Therapeutics 新股份。最後，Ameritas Advisory Services LLC 在第二季度購買了價值約 77,000 美元的 Axsome Therapeutics 新股份。目前，81.49% 的股票由機構投資者持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In related news, COO Mark L. Jacobson sold 10,000 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $115.96, for a total value of $1,159,600.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Herriot Tabuteau sold 10,558 shares of the firm's stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $148.18, for a total value of $1,564,484.44. Following the transaction, the chief executive officer directly owned 7,229 shares of the company's stock, valued at $1,071,193.22. The trade was a 59.36% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 407,959 shares of company stock worth $52,645,040. Insiders own 22.30% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席運營官 Mark L. Jacobson 於 9 月 22 日星期一出售了 10,000 股該股票。股票以 115.96 美元的平均價格出售，總價值為 1,159,600.00 美元。該交易在 SEC 的法律文件中披露，相關信息可通過此超鏈接獲取。此外，首席執行官 Herriot Tabuteau 於 12 月 4 日星期四出售了 10,558 股公司的股票。股票以 148.18 美元的平均價格出售，總價值為 1,564,484.44 美元。交易後，首席執行官直接持有 7,229 股公司的股票，價值 1,071,193.22 美元。該交易使其持股減少了 59.36%。該銷售的披露信息可在 SEC 文件中找到。在過去 90 天內，內部人士出售了價值 52,645,040 美元的 407,959 股公司股票。內部人士持有公司 22.30% 的股票。</p>
</div><h2>Axsome Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Axsome Therapeutics 價格表現</h2>
</div><ul>
<li>Struggling Axsome Stock Could Bounce Back on Drug Trial Success</li>
</ul>
<div class="lb-trans"><ul>
<li>struggling Axsome 股票可能因藥物試驗成功而反彈</li>
</ul>
</div><p>Shares of AXSM opened at $149.22 on Friday. The firm has a fifty day moving average price of $134.97 and a 200 day moving average price of $118.87. The stock has a market cap of $7.52 billion, a PE ratio of -31.95 and a beta of 0.48. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. Axsome Therapeutics, Inc. has a 1-year low of $75.56 and a 1-year high of $152.94.</p>
<div class="lb-trans"><p>AXSM 的股票在週五開盤價為 149.22 美元。該公司的 50 日移動平均價格為 134.97 美元，200 日移動平均價格為 118.87 美元。該股票的市值為 75.2 億美元，市盈率為-31.95，貝塔值為 0.48。該公司的債務與股本比率為 1.66，流動比率為 1.57，速動比率為 1.50。Axsome Therapeutics, Inc.的 1 年最低價為 75.56 美元，1 年最高價為 152.94 美元。</p>
</div><p>Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The business had revenue of $170.99 million for the quarter, compared to analysts' expectations of $162.96 million. Axsome Therapeutics's quarterly revenue was up 63.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.</p>
<div class="lb-trans"><p>Axsome Therapeutics（NASDAQ:AXSM - 獲取免費報告）最近在 11 月 3 日星期一發布了季度收益數據。該公司報告季度每股收益（EPS）為（0.94 美元），低於市場共識預期的（0.82 美元）0.12 美元。Axsome Therapeutics 的股本回報率為-277.31%，淨利潤率為-40.90%。該業務在本季度的收入為 1.7099 億美元，而分析師預期為 1.6296 億美元。Axsome Therapeutics 的季度收入同比增長 63.2%。作為一個整體，賣方分析師預計 Axsome Therapeutics, Inc.在當前年度將發佈-2.79 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>Why this is an Awesome Time to Buy Axsome Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼現在是購買 Axsome Therapeutics 的絕佳時機</li>
</ul>
</div><p>Several equities analysts recently weighed in on the company. Needham &amp; Company LLC restated a &#34;buy&#34; rating and issued a $154.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, November 4th. Royal Bank Of Canada upped their price objective on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, November 4th. Mizuho lifted their price target on Axsome Therapeutics from $200.00 to $202.00 and gave the stock an &#34;outperform&#34; rating in a report on Thursday, November 6th. Morgan Stanley upped their price objective on Axsome Therapeutics from $194.00 to $196.00 and gave the company an &#34;overweight&#34; rating in a report on Tuesday, November 4th. Finally, B. Riley started coverage on shares of Axsome Therapeutics in a research report on Wednesday, October 1st. They set a &#34;buy&#34; rating and a $179.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $179.88.</p>
<div class="lb-trans"><p>幾位股票分析師最近對該公司進行了評估。Needham &amp; Company LLC 重申了對 Axsome Therapeutics 股票的 “買入” 評級，並在 11 月 4 日的研究報告中給出了 154.00 美元的目標價。加拿大皇家銀行將 Axsome Therapeutics 的目標價從 189.00 美元上調至 198.00 美元，並在 11 月 4 日的研究報告中給予該公司 “跑贏大盤” 的評級。瑞穗證券在 11 月 6 日的報告中將 Axsome Therapeutics 的目標價從 200.00 美元上調至 202.00 美元，並給予該股票 “跑贏大盤” 的評級。摩根士丹利在 11 月 4 日的報告中將 Axsome Therapeutics 的目標價從 194.00 美元上調至 196.00 美元，並給予該公司 “增持” 的評級。最後，B. Riley 在 10 月 1 日的研究報告中開始覆蓋 Axsome Therapeutics 的股票。他們設定了 “買入” 評級和 179.00 美元的目標價。一位股票研究分析師對該股票給予了強烈買入評級，十六位給予了買入評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該股票的共識評級為 “適度買入”，共識目標價為 179.88 美元。</p>
</div><p><strong>View Our Latest Report on Axsome Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Axsome Therapeutics 的最新報告</strong></p>
</div><h2>About Axsome Therapeutics</h2>
<div class="lb-trans"><h2>關於 Axsome Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.</p>
<div class="lb-trans"><p>Axsome Therapeutics, Inc.是一家生物製藥公司，專注於在美國開發針對中樞神經系統（CNS）疾病的新療法。該公司的商業產品組合包括 Auvelity（右美沙芬 - 布普洛尼），這是一種具有多重作用的 N-甲基-D-天冬氨酸受體拮抗劑，適用於治療重度抑鬱症；以及 Sunosi（索利美特），這是一種用於治療嗜睡症或阻塞性睡眠呼吸暫停患者的白天過度嗜睡的藥物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Axsome Therapeutics</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?</li>
<li>Best Aerospace Stocks Investing</li>
<li>Gates Foundation Sells MSFT Stock—Should Investors Be Worried?</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>MarketBeat Week in Review – 12/1 - 12/5</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Axsome Therapeutics</li>
<li>投資者如何識別併成功交易缺口下跌股票</li>
<li>Ulta 的股票可能會迎來反彈——20% 的上漲空間？</li>
<li>最佳航空航天股票投資</li>
<li>比爾和梅琳達·蓋茨基金會出售 MSFT 股票——投資者應該擔心嗎？</li>
<li>股息捕捉策略：您需要知道的事項</li>
<li>MarketBeat 週迴顧 – 12/1 - 12/5</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AXSM?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有 AXSM 的情況嗎？</strong> 訪問 HoldingsChannel.com 以獲取 Axsome Therapeutics, Inc.（NASDAQ:AXSM - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVhTTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AXSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Axsome Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Axsome Therapeutics 嗎？</h2>
</div><p>Before you consider Axsome Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Axsome Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Axsome Therapeutics 並不在名單上。</p>
</div><p>While Axsome Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Axsome Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Kennedy Capital Management LLC 增持了 Axsome Therapeutics, Inc. $AXSM 的股份